Natco Pharma stock gets an INR 12.79 billion rights issue

Natco Pharma (ISIN INE987B01026) has lifted its proposed investment in US biotechnology company eGenesis to USD 16.70 million, according to Business Standard on September 29, 2026. The transaction adds a fresh strategic angle as the drugmaker also prepares a large equity raise.

eGenesis investment reaches USD 16.70 million

Natco Pharma will invest USD 13.70 million through Natco Pharma Canada and USD 3.00 million through Natco Pharma USA, with completion expected by October 31, 2026. The investment uses convertible promissory notes carrying 8.00 percent compound interest, and Natco's total investment in eGenesis would reach USD 24.70 million after completion, Business Standard reported.

eGenesis is developing genetically modified pig organs for transplantation into humans. For Natco, the move extends capital deployment beyond conventional generic medicines and links the company to an early-stage biotechnology platform.

Rights issue sets INR 750 price

Natco's board approved a rights issue of up to INR 12.79 billion at INR 750 per share on September 25, 2026. The offer covers up to 170,580,82 shares and gives eligible holders two new shares for every 21 shares held, according to DSIJ.

At full subscription, the issue would expand Natco's pre-issue share base by 9.50 percent and equal 31.00 percent of fiscal-year 2026 revenue. The record date is October 1, 2026, while subscription is scheduled from October 12 through October 22, 2026, with rights renunciation from October 12 through October 16, 2026, BusinessLine reported.

June quarter shows lower scale

For the quarter ended June 30, 2026, Natco reported consolidated total income of INR 7.944 billion and profit after tax of INR 2.065 billion. The figures provide the latest operating base against which the INR 12.79 billion fundraising should be assessed, with both figures reported in the quarterly financial table carried by The Economic Times.

On NSE, Natco Pharma was at INR 839.10 at 10:57 a.m. IST on September 29, 2026, up 1.28 percent from INR 828.55. The stock's reported 52-week range was INR 789.00 to INR 1,226.80, while market capitalization stood at INR 150.3 billion on September 25, 2026.

Capital allocation becomes central

The combination of an INR 12.79 billion rights issue and the USD 16.70 million eGenesis commitment puts capital allocation at the center of Natco's near-term story. The rights issue creates room for acquisitions and product investment, while the June-quarter figures show the earnings base that must support the expansion.

More news and analyses on Natco Pharma stock